论文部分内容阅读
目的对利托君治疗胎膜早破型先兆早产的疗效进行观察和分析。方法随机选取本院收治的胎膜早破型早产患者100例作为研究对象,根据是否运用利托君治疗分为观察组和对照组。将用100mg利托君溶于500ml葡萄糖注射液中,对观察组患者行静脉滴注,对照组用25%的硫酸镁溶液治疗。结果观察组患者平均宫缩时间为(61.34±8.84)min,孕龄延长(30.94±5.68)d,而不良反应只有4例,占6.78%,新生儿全部存活,平均体重为(2.87±0.24)kg。对照组治疗效果不如观察组,患者平均宫缩时间为(111.57±10.46)min,孕龄延长(21.57±3.84)d,不良反应较多共有11例,占26.83%,新生儿有3名死亡,存活率为92.68%,平均体重较轻,仅为(2.19±0.16)kg。结论利托君治疗胎膜早破型先兆早产疗效显著,能缩短患者的宫缩时间,延长孕龄,提高新生儿存活率,增强新生儿体质。
Objective To observe and analyze the efficacy of Rituxurium in the treatment of premature rupture of membranes of premature rupture of membranes. Methods 100 cases of preterm premature rupture of membranes treated in our hospital were selected as the research object. According to whether the treatment with orotidine was divided into observation group and control group. Will be 100mg Ricardon dissolved in 500ml glucose injection, the observation group patients intravenous drip, the control group with 25% magnesium sulfate solution treatment. Results The average duration of contractions was (61.34 ± 8.84) min and the gestational age was prolonged (30.94 ± 5.68) days in the observation group, while only 4 patients (6.78%) had adverse reactions. The neonates survived with an average body weight of (2.87 ± 0.24) kg. The mean curative time was (111.57 ± 10.46) min and the gestational age was longer (21.57 ± 3.84) d in the control group. The total number of adverse reactions was 11.8% (26.83%), and 3 newborns died. The survival rate was 92.68%, the average body weight was lighter, only (2.19 ± 0.16) kg. Conclusion Rituximab treatment of premature rupture of membranes premature rupture of the effect of significant premature birth, can shorten the patient’s contractions time, prolong the gestational age, improve neonatal survival rate and enhance the physical fitness of newborns.